Abstract

Gene transfer using adeno-associated viral (AAV) vectors has made tremendous progress in the last decade and has achieved cures of debilitating diseases such as hemophilia A and B. Nevertheless, progress is still being hampered by immune responses against the AAV capsid antigens or the transgene products. Immunosuppression designed to blunt T cell responses has shown success in some patients but failed in others especially if they received very high AAV vectors doses. Although it was initially thought that AAV vectors induce only marginal innate responses below the threshold of systemic symptoms recent trials have shown that complement activation can results in serious adverse events. Dorsal root ganglia toxicity has also been identified as a complication of high vector doses as has severe hepatotoxicity. Most of the critical complications occur in patients who are treated with very high vector doses indicating that the use of more efficient AAV vectors to allow for dose sparing or giving smaller doses repeatedly, the latter in conjunction with antibody or B cell depleting measures, should be explored.

MeSH

Immune System Diseases, Hemophilia A, Immunosuppression Therapy, Cells, Therapeutics, T-Lymphocytes, Genes, Immunity, Innate, B-Lymphocytes

Cited by

• Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. Nat Commun, 2023
• Efficacy and muscle safety assessment of fukutin-related protein gene therapy. Mol Ther Methods Clin Dev, 2023
• Lentiviral vectors for precise expression to treat X-linked lymphoproliferative disease. Mol Ther Methods Clin Dev, 2024
• Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B. Pharmaceutics, 2024
• AAV9-mediated gene delivery to liver grafts during static cold storage in a rat liver transplant model. Front Transplant, 2023
• Gene therapy: principles, challenges and use in clinical practice. Wien Klin Wochenschr, 2025
• Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques. Mol Ther, 2024
• Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age. Mol Ther, 2025
• AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat Commun, 2025
• Delivery of gene editing therapeutics. Nanomedicine, 2023
• Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial. Am J Respir Crit Care Med, 2024
• Identification of a novel neutralization epitope in rhesus AAVs. Mol Ther Methods Clin Dev, 2024
• CRISPR: fundamental principles and implications for anaesthesia. Br J Anaesth, 2025
• Advances in Gene Therapy for Rare Diseases: Targeting Functional Haploinsufficiency Through AAV and mRNA Approaches. Int J Mol Sci, 2025
• AAV yield, bioactivity, and particle heterogeneity are impacted by genome size and non-coding DNA elements. Mol Ther Methods Clin Dev, 2025
• Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction. J Thromb Haemost, 2024
• Brain gene therapy with Trojan horse lipid nanoparticles. Trends Mol Med, 2023
• Novel assay format for total anti-adeno-associated virus antibody detection with low capsid consumption and built-in specificity control. Bioanalysis, 2024
• AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy. Microorganisms, 2023
• The curious case of AAV immunology. Mol Ther, 2025